Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19968462 | 0.85 | TLR7 (0.46) | TLR7TLR8ADORA3 | |
| SCHEMBL6106242 | 0.85 | TLR7 (0.56) | TLR7TLR8ADORA3 | |
| SCHEMBL19968181 | 0.83 | TLR7 (0.44) | TLR7TLR8 | |
| SCHEMBL24409692 | 0.81 | CYP1A2 (0.38) | TLR7TLR8MAPK1 | |
| SCHEMBL4246380 | 0.81 | TLR7 (0.39) | TLR7TLR8 | |
| SCHEMBL6105437 | 0.81 | TLR7 (0.63) | TLR7TLR8LMNA | |
| SCHEMBL3178411 | 0.78 | TLR7 (0.60) | TLR7TLR8LMNA | |
| SCHEMBL1486471 | 0.78 | TLR7 (0.58) | TLR7TLR8ESR1ESR2LMNA | |
| SCHEMBL4247998 | 0.78 | TLR7 (0.39) | TLR7TLR8ESR1LMNA | |
| SCHEMBL10123169 | 0.77 | TLR7 (0.50) | TLR7TLR8LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144865-A1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-05-12 | — | — | US | disclosed |
| US-20210277038-A1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2021-09-09 | — | — | US | disclosed |
| EP-3510036-B1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2021-07-21 | — | — | EP | disclosed |
| WO-2018046460-A1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277038-A1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | MAVS, IRF3, MYD88 | TLR7 8/4885TLR8 45/4885ESR1 3474/4885 |
| US-20220144865-A1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | MAVS, IRF3, MYD88 | TLR7 8/4885TLR8 45/4885ESR1 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.